Alcohol Addiction - Pipeline Review, H2 2016

Description: Alcohol Addiction - Pipeline Review, H2 2016

Summary

‘Alcohol Addiction - Pipeline Review, H2 2016’, provides an overview of the Alcohol Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alcohol Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alcohol Addiction and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Alcohol Addiction
- The report reviews pipeline therapeutics for Alcohol Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Alcohol Addiction therapeutics and enlists all their major and minor projects
- The report assesses Alcohol Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Alcohol Addiction

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Alcohol Addiction
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alcohol Addiction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

List of Figures
Introduction
Report Coverage
Alcohol Addiction Overview
Therapeutics Development
Pipeline Products for Alcohol Addiction - Overview
Pipeline Products for Alcohol Addiction - Comparative Analysis
Alcohol Addiction - Therapeutics under Development by Companies
Alcohol Addiction - Therapeutics under Investigation by Universities/Institutes
Alcohol Addiction - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Alcohol Addiction - Products under Development by Companies
Alcohol Addiction - Products under Investigation by Universities/Institutes
Alcohol Addiction - Companies Involved in Therapeutics Development
AbbVie Inc.
Adex Therapeutics Ltd
Adial Pharmaceuticals, LLC
Astraea Therapeutics, LLC
AstraZeneca Plc
Bionex Pharmaceuticals LLC
Bioprojet SCR
Cerecor Inc.
Curemark, LLC
Eli Lilly and Company
Ethypharm S.A.
Euthymics Bioscience, Inc.
H. Lundbeck A/S
Heptares Therapeutics Limited
Indivior Plc
Johnson & Johnson
Kinnov Therapeutics SAS
Kyorin Pharmaceutical Co., Ltd.
Lohocla Research Corporation
Omeros Corporation
Pfizer Inc.
SK Biopharmaceuticals Co., Ltd.
Tonix Pharmaceuticals Holding Corp.
VM Discovery, Inc.
XenoPort, Inc.
Zynerba Pharmaceuticals, Inc.
Alcohol Addiction - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(cyproheptadine hydrochloride + prazosin hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(disulfiram + selegiline) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
A-705253 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-1212 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gabapentin enacarbil ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GET-73 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibudilast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JDTic - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-5234801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
saracatinib difumarate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKL-10406 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Alcohol Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Oxytocin Receptor for Alcohol Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize NOP for Pain and Alcohol Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

Small Molecules to Antagonize GABAA1 for Alcohol Addiction and Anxiety - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VMD-2202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Alcohol Addiction - Dormant Projects

Alcohol Addiction - Discontinued Products

Alcohol Addiction - Product Development Milestones

Featured News & Press Releases

Jun 29, 2016: MediciNova Announces Results from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana

May 25, 2016: MediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol Dependence to be Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana


Dec 09, 2015: MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting

Oct 13, 2015: Addex' ADX71441 Demonstrates Robust Efficacy in Multiple Preclinical Models of Alcohol Use Disorder

Oct 01, 2015: XenoPort Announces Plan to Focus on its Growing HORIZANT Business and Names Vincent J. Angotti Chief Executive Officer and Director

Jun 30, 2015: MediciNova Announces the Completion of Enrollment in Clinical Trial of MN-166 in Alcohol Dependence

Jun 25, 2015: XenoPort Announces Initiation by NIAAA of Clinical Trial of HORIZANT in Patients with Alcohol Use Disorder

Jun 24, 2015: MediciNova Announces Presentation of Interim Data from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence at the 38th Annual RSA (Research Society on Alcoholism) Scientific Meeting

Jan 11, 2015: XenoPort Provides Highlights of HORIZANT Prescription Trends and Update on Development for Alcohol Use Disorder

Jan 07, 2015: Addex and NIAAA Enter Collaboration to Evaluate ADX71441 in Alcohol Use Disorder

Nov 26, 2014: Biotie: UK's Nice Issues Positive Final Guidance For Selincro
Nov 26, 2014: Drug recommended to help cut drink dependence

Sep 09, 2014: XenoPort and the NIAAA Announce Clinical Trial Agreement to Study HORIZANT as a Potential Treatment for Alcohol Use Disorder

Jul 10, 2014: NICE recommends nalmefene treatment for alcohol dependence

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Number of Products under Development for Alcohol Addiction, H2 2016
Number of Products under Development for Alcohol Addiction - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Alcohol Addiction - Pipeline by AbbVie Inc., H2 2016
Alcohol Addiction - Pipeline by Addex Therapeutics Ltd, H2 2016
Alcohol Addiction - Pipeline by Adial Pharmaceuticals, LLC, H2 2016
Alcohol Addiction - Pipeline by AstraAea Therapeutics, LLC, H2 2016
Alcohol Addiction - Pipeline by AstraZeneca Plc, H2 2016
Alcohol Addiction - Pipeline by Bionex Pharmaceuticals LLC, H2 2016
Alcohol Addiction - Pipeline by Bioprojet SCR, H2 2016
Alcohol Addiction - Pipeline by Cerecor Inc., H2 2016
Alcohol Addiction - Pipeline by Curemark, LLC, H2 2016
Alcohol Addiction - Pipeline by Eli Lilly and Company, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/3821612/](http://www.researchandmarkets.com/reports/3821612/)
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Alcohol Addiction - Pipeline Review, H2 2016
Web Address: http://www.researchandmarkets.com/reports/3821612/
Office Code: SCBRG7VX

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐
First Name: ___________________________________________ Last Name: ___________________________________________
Email Address: * _______________________________________
Job Title: _____________________________________________
Organisation: __________________________________________
Address: ______________________________________________
City: __________________________________________________
Postal / Zip Code: ______________________________________
Country: _______________________________________________
Phone Number: __________________________________________
Fax Number: ____________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World